ClearPoint Neuro (CLPT) announced the acquisition of San Diego based, Irras Holdings. Its cornerstone product is the IRRAflow system, an FDA-cleared and CE-marked platform which integrates continuous irrigation, aspiration, and real-time intracranial pressure monitoring. The deal brings more than 50 active customers to the ClearPoint Neuro installed base and 10 additional patent families. Based on management’s current forecasts for ClearPoint Neuro’s business and its assessment of the Irras business, the total 2026 combined revenue for the two companies is expected to be in the range of $54M to $60M.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLPT:
- Largest borrow rate increases among liquid names
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
- Why Is ClearPoint Neuro Stock (CLPT) Up Today?
- UniQure (QURE) Stock Jumps 248% on Huntington’s Trial Results. Analysts Raise Price Targets
- Unusually active option classes on open September 24th